Biodexa Pharmaceuticals plc · NASDAQ:BDRX
Biodexa Pharmaceuticals — Investor Presentation (September 2026)
22 slides from Biodexa Pharmaceuticals's investor presentation, September 2026
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ:BDRX September 2026
Slide 2: Disclaimer & cautionary language regarding forward-looking statements
Disclaimer & cautionary language regarding forward-looking statements The following presentation, including the information communicated during any delivery of the presentation, and any document or material distributed at or in connection with the presentation (together, the “Presentation”), has bee
Slide 3: Highlights
Highlights • Nasdaq listed • Focused on rare GI oncology diseases • Phase 3 program in FAP* • Phase 1 ready asset in GIST** • Semi-virtual organization • Near term milestones * Familial Adenomatous Polyposis ** GastroIntestinal Stromal Tumors 3
Slide 4: Company Strategy
Company Strategy BUILD DEVELOP PARTNER Build pipeline of assets Develop assets through License out to pharma focused on the GI / GI next stage/s of validation partners oncology space Progress through proof- Partners sponsor late- Target assets in late pre- of-concept stage program and clinical / ear
Slide 5: Current pipeline
Current pipeline Grant Indication Preclinical Phase 1 Phase 2 Phase 3 Funding SPONSORED: Familial CPRIT: MTX230 eRapa Adenomatous Orphan $20 million to (rapamycin) Polyposis (FAP) fund Phase 3 Gastrointestinal MTX240 Stromal Tumors Orphan (Molecular glue) (GIST) INVESTIGATOR INITIATED: Non-Muscle In
Slide 6: MTX230
MTX230 eRapa (rapamycin) for treatment of Familial Adenomatous Polyposis (FAP) 6
Slide 7: Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis (FAP) • Caused by autosomal dominant APC gene mutation, 70-75% hereditary • Characterized by 100s /1,000s of adenomatous polyps in the GI tract • If untreated, near 100% of patients develop colorectal cancer • Standard of care is active screening polypectomy colect
Slide 8: FAP biology / MTX230 MoA
FAP biology / MTX230 MoA • In APC mutation, Wnt signaling is constitutively active, cells over-proliferate polyp formation • Wnt signaling cross-talks with mTOR pathway, a gateway to several biosynthetic pathways that fuel rapid cell proliferation • Rapamycin is a well characterized and approved m
Slide 9: eRapa vs Rapamune
eRapa vs Rapamune® • Rapamycin is limited by poor bioavailability and inter- patient PK variability 1500 • eRapa was formulated using a proprietary 0.3mg/kg eRapa nanoprecipitation process: 0.6mg/kg eRapa • enteric coated micro-particles dissolving pH>6.8 1.2mg/kg eRapa designed to reduce effect of
Slide 10: MTX230: Phase 2 prevention of progression in FAP
MTX230: Phase 2 in FAP Prevention of progression in FAP 12 month data Change from baseline (%) Cohort 2 (n=9): 89% non-progression, 29% decrease in median polyp burden 10
Slide 11: Global eRapa Phase 3 trial: Trial Design and Sites
Global eRapa Phase 3 trial Trial Design and Sites TRIAL DESIGN GLOBAL REACH • Placebo-controlled, double- blind, registrational • n=168 • Inclusion: high risk patients with germline or phenotypic FAP diagnosis • Patient Stratification: • Intact colon vs post-surgery • Stage 3 / higher duodenal polyp
Slide 12: Global eRapa Phase 3: Primary Endpoint and Timeline
Global eRapa Phase 3 Primary Endpoint and Timeline PRIMARY ENDPOINT: Progression-Free Survival (PFS) Composite Clinical Progression Measure Surgery /meets criteria Advancement of Diagnosis of high-grade Death by any cause for major surgery Spigelman Stage dysplasia or cancer Endpoints agreed in Type
Slide 13: MTX240
MTX240 Molecular glue for treatment of GastroIntestinal Stromal Tumors (GIST)
Slide 14: GastroIntestinal Stromal Tumors (GIST)
GastroIntestinal Stromal Tumors (GIST) • Tumors arise from Interstitial Cells of Cajal (ICCs) in GI wall, responsible for peristalsis3 • GIST tumors occur in the stomach (~70%), small intestine (~25%) and esophagus (<5%)4 • Minority (10%) of GISTs are ‘wild type’ and driven by SDH, BRAF or NF1 mutat
Slide 15: GIST biology / MTX240 MoA
GIST biology / MTX240 MoA • Tumors arise from Interstitial Cells of Cajal (ICCs) • ICCs normally express the tyrosine kinase KIT (CD117) becomes constitutively activated in GIST • Mutation(s) in KIT or PDGFRA hyperactivation of PI3K and MAPK signaling • MTX240 is a molecular glue developed to Ph
Slide 16: GIST – current and potential new therapies
GIST – current and potential new therapies • Surgical resection (when feasible) KIT PDGFR WILD TYPE COMPOUND PDGFR • Tyrosine Kinase Inhibitors (TKIs) Primary ATP-binding pocket Activation Loop D842V SDH insufficient BRAF NF1 exon 9 exon 11 exon 13 exon 14 exon 17 exon 18 V600E inhibit mutant KIT /
Slide 17: MTX240 – observed response in cancer types
MTX240 – observed response in cancer types • MTX240 efficacy demonstrated in 9 of 9 GIST cell lines • Highly potent. Orally bioavailable • MTX240 is not toxic in ICCs or any cells that do not express BOTH SLFN12 and PDE3A • Certain other healthy cell types (eg. MKs) express PDE3A, conferring on- tar
Slide 18: MTX240 – preclinical proof of concept
MTX240 – preclinical proof of concept • Knock-in / knock-out studies confer sensitivity / resistance, respectively • PDX studies demonstrate efficacy in GISTs with different KIT mutations (p<0.01)14: 18
Slide 19: MTX240 – Planned Phase 1 program
MTX240 – Planned Phase 1 program Phase Ph 1a: Dose Escalation 1b/2a: Dose Optimization Subjects Advanced GIST patients Advanced GIST patients (n = 8-18) (n = 10-20 in each of 2 cohorts) Dose 0.15mg QW up to 0.3mg QW Phase 1a MTD plus one other dose Primary • Safety, tolerability • Safety, tolerabili
Slide 20: Cap table (as of September 15, 2026)
Cap table (as of September 15, 2026) WAV ex. Ordinary shares ADSs % Price % Issued 209,695,831 4,193,914 100.0% 45.3% Pre-funded warrants 347 0.0% 0.0% Issued - in the money 4,194,261 100.0% 45.3% Warrants - Series L 609,756 $ 16.40 6.6% Warrants - Series P 4,408,436 $ 1.05 47.7% Warrants - Other 36
Slide 21: Thank You
biodexa pharmaceuticals e Thank You 21
Slide 22: References
References 1. National Organisation for Rare Disorders: https://rarediseases.org/rare-diseases/familial-adenomatous-polyposis/ 2. Orphanet: https://link.springer.com/article/10.1186/1750-1172-4-22 3. Usama, F., et al. (2025). Update on gastrointestinal stromal tumors (GISTs) with a focus on molecula
Biodexa Pharmaceuticals — Investor Presentation (September 2026) on 6ix